1.淋巴瘤的发生发展机制研究，尤其是TP53突变弥漫性大B细胞淋巴瘤及中枢淋巴瘤的机制研究。

2.淋巴瘤的肿瘤微环境。

3.淋巴瘤的规范诊治和疗效评估💇‍♀️。

4.难治复发淋巴瘤和多发性骨髓瘤的CAR-T和双抗治疗、药物临床试验👨🏽‍🎤、NGS技术监测淋巴瘤的疗效、构建mini-PDX模型筛选最佳治疗策略。

1.The pathogenesis and progression of lymphoma🎖🧎🏻，especially focus on TP53 mutation DLBCL and central nervous lymphoma.

2.The tumor microenvironment of lymphoma.

3.Standard diagnosis, treatment and efficacy evaluation of lymphoma

4.Clinical trials of CAR-T therapy and double antibody therapy for refractory relapsed lymphoma and multiple myeloma🔱，Adopt NGS technique to monitor the efficacy of lymphoma and construct mini-PDX model to screen the best treatment strategy for lymphoma

上海顺盈娱乐平台附属同济医院血液科副主任医师🧑，副教授，淋巴瘤MDT负责人⛹️‍♀️，美国mayo clinic血液中心访问学者🚴🏻‍♀️。现为中国抗癌协会血液学转化医学委员会青年委员🥶，中华医学会上海分会血液学组青年副主任委员，上海市医师协会第一届肿瘤精准诊疗专业委员会委员🙏🏻，上海市女医师协会血液学专业委员会委员🤽，上海市医学会心身医学委员，上海市医学会输血学会青年委员，上海市医学会血液学专科分会淋巴瘤及骨髓瘤学组委员。3次至美国mayo clinic 进修骨髓移植和淋巴瘤的基础与临床研究🌉🤧。迄今为止🤦🏿，主持及参与多项国家自然科学基金项目及上海市科委自然科学基金👵🏼，发表论文20余篇🔲，参加编著论著3部🤷🏽，研究成果多次被美国血液年会以壁报收录。

Deputy Chief Physician and Associate Professor of the Department of Hematology, Tongji Hospital, Tongji University, Supervisor of Lymphoma MDT, Visiting Scholar at Mayo Clinic, Rochester. Youth member of the Hematology Translational Medicine Committee of the Chinese Anti-Cancer Association, Vice Chairman of the Youth Committee of Branch of hematology of Shanghai Medical Association in China, Member of 1st Cancer Precision Diagnosis and Treatment Professional Committee of Shanghai Medical Doctor Association，Member of the Hematology Committee of the Shanghai Women Physicians Association, Member of the Psychosomatic Medicine Committee of the Shanghai Medical Association, Youth member of the Blood Transfusion Society of the Shanghai Medical Association, Member of the Lymphoma and Myeloma Group of the Hematology Branch of the Shanghai Medical Association.

I have been to Mayo Clinic in the United States for 3 times to study basic and clinical research in bone marrow transplantation and lymphoma. So far, I have presided over and participated in a number of projects of the National Natural Science Foundation of China and the Natural Science Foundation of the Shanghai Municipal Science and Technology Commission, published more than 20 papers, participated in the compilation of 3 monographs, and the research results have been included in the poster of the American Blood Annual Meeting for many times.

主持及参与课题:

1.国家自然基金面上项目，82470227，靶向CSF1R重编程肿瘤巨噬细胞逆转TP53突变弥漫性大B 细胞淋巴瘤CAR-T治疗抵抗的疗效及机制研究🚴🏽‍♀️，2025.01-2028.12🛠👨🏻‍🍳，48.50万🤵🏻，主持🤌🦹🏼‍♀️。

2.上海申康医院发展中心第二轮《促进市级医院临床技能与临床创新三年行动计划（2023-2025年）》模拟RCT研究项目，SHDC2024CRI039🧚🏽‍♀️，维泊妥珠单抗联合R-CHP与R-CHOP治疗弥漫性大B细胞淋巴瘤患者的疗效和安全性比较👨‍👧‍👦，2023.12.01-2025.9.30,15万元，主持🦵🏻，在研🛑👎🏼。

3.国家自然基金青年科学基金项目,81600156,《活化T细胞核因子（NFAT）诱导PD-1/TIM-3调控淋巴瘤T细胞耗竭的机制研究》, 2017.01-2019.12，18万元，主持。

4.上海市卫生健康委员会面上项目🏄🏽‍♂️，202240339，《低剂量放疗序贯PD-1抗体治疗难治复发性霍奇金淋巴瘤患者疗效及安全性研究》，2023.1-2025.12，10万🖕🏿8️⃣，主持。

5.国家自然基金科学基金区域联合项目📮，U23A20418，《TP53突变定向进化诱导弥漫性大B细胞淋巴瘤发生发展和免疫逃逸的机制研究》🙍🏿，2014.1-2017.12😺，260万元🧑🏿，主要参与者👩🏿‍🏫。

6.国家自然科学基金重点项目，81830004👨🏽‍🚒，《TLR4通路介导的内皮细胞激活促进CART细胞治疗相关sCRS的发生》，2019.1-2023.12，293万元，主要参与者。

7.上海申康医院发展中心促进市级医院临床技能与临床创新三年行动计划（2020-2022年），SHDC2020CR6005,“弥漫大B细胞淋巴瘤专病队列数据库建设”，187万，2020.12.1-2022.9.30,主要参与者🧑🏼‍🌾。

8.美国NIH Lymphoma Specialized Program of Research Excellence (SPORE)，P50CA097274-11 CDA1，The role of Galectin-9 in IL-12/TIM-3-mediated T-cell exhaustion in B-cell non-Hodgkin lymphoma👩‍🦰，07/01/2012- 06/30/2013，300万美金，主要参与者👸🏻。

科技奖励🧑‍🦼‍➡️：

1. 科研成果“附红细胞体病诊疗和研究体系的创新与应用”获2014年度上海市科技进步奖二等奖🙎🏿。

2. 科研成果“双相培养体系及分子标志物检测在正常核型急性白血病诊治中的作用”获2011年度教育部科技进步二等奖。

Grants:

1.The National Natural Science Fund, No. 82470227,Efficacy and mechanism of targeting CSF1R reprogrammed tumor macrophages to reverse CAR-T therapy resistance in TP53-mutant diffuse large B-cell lymphoma, 2025.01-2028.12, RMB 485,000, Role: PI.

2.Data Sharing and Emulation of Clinical Trials, CCS-DASET，(No. SHDC2024CRI039), Comparison of efficacy and safety of Vepostuzumab combined with R-CHP versus R-CHOP in patients with diffuse large B-cell lymphoma，2023.12.01-2025.9.30,RMB 150,000👨🏻‍🏫，Role: PI.

3.The National Natural Science Fund, No. 81600156, T cell exhaustion regulated by Nuclear Factor of Activated T cells via inducing PD-1 and TIM-3 expression in lymphoma🤌🏻，2017.01-2019.12, RMB 180,000, Role: PI.

4.The Scientific Research Funds from Shanghai Municipal Public Health Bureau, 202240339, Efficacy and safety of low-dose radiotherapy sequential PD-1 antibody therapy in patients with refractory relapsed Hodgkin lymphoma，2023.1-2025.12, RMB 100,000, Role: PI.

5.The National Natural Science Fund, No. U23A20418🔷，To explore the mechanism of pathogenesis, development and immune escape in diffuse large B-cell lymphoma induced by directional evolution of TP53 mutation,2024.1-2027.12🧓，RMB 2,600,000，Role: Participant.

6.The Key Project of Natural Science Foundation of China, No. 81830004, TLR4 pathway-mediated endothelial cell activation promotes the occurrence of CART cell therapy-associated sCRS, 2019.1-2023.12, RMB 2,930,000, Role: Participant.

7.Clinical Research Plan of SHDC （2020-2022）,No. SHDC2020CR6005,Construction of the database of the specialized cohort of diffuse large B-cell lymphoma,2020.12.1- 2022.9.30,RMB 1,870,000,Role: Participant.

8.NIH Lymphoma Specialized Program of Research Excellence (SPORE), P50CA097274-11 CDA1,The role of Galectin-9 in IL-12/TIM-3 -mediated T-cell exhaustion in B-cell non-Hodgkin lymphoma,07/01/2012- 06/30/2013,$50,000, Role: Participant.

Scientific Awards:

1.     The innovation and application for the diagnosis and treatment and research system for Eperythrozoon disease, Shanghai scientific and technological progress, second prize, 2014

2.     Role of establishment of a biphase culture system and detection of molecular genetics alterations in the diagnosis and treatment in acute leukemia patients with normal karotype. The ministry of education of science and technology progress, second prize, 2010

代表论文（Publications，Full length, peer-reviewed, original articles）：

Pan M, Yang P, Wang F, Luo X, Li B, Ding Y, Lu H, Dong Y, Zhang W*, Xiu B*, Liang A*. Whole Transcriptome Data Analysis Reveals Prognostic Signature Genes for Overall Survival Prediction in Diffuse Large B Cell Lymphoma. Front Genet. 2021 Jun 9;12:648800.

Jinyuan Lu, You Wu, Bing Li, Xiu Luo, Wenjun Zhang, Yu Zeng, Jianfei Fu, Aibin Liang, Bing Xiu*, Predictive value of serological factors, maximal standardized uptake value and ratio of Ki67 in patients diagnosed with non-Hodgkin’s lymphoma, Oncology Letters,2020,20(4):47

B Xiu#, Y Lin, DM Grote, SC Ziesmer, MP Gustafson, ML Maas, ZZhang, AB Dietz, LF Porrata, AJ Novak, AB Liang, ZZ Yang*, SM Ansell*, IL-10 induces the development of immunosuppressive CD14+HLA-DRlow/- monocytes in B-cell non-Hodgkin lymphoma, Blood Cancer Journal, 2015, (5), e328👨🏻‍🏫，July，31

Zhu J, Zhu X, Xie F, Ding Y, Lu H, Dong Y, Li P, Fu J, Liang A, Zeng Y, Xiu B*, Case report: Circulating tumor DNA technology displays temporal and spatial heterogeneity in Waldenström macroglobulinemia during treatment with BTK inhibitors. Pathol Oncol Res. 2023,29:1611070.

Fang X#, Xiu B#, Yang Z, Qiu W, Zhang L, Zhang S, Wu Y, Zhu X, Chen X, Xie S, Yi X, Liang A, Zeng Y*,The expression and clinical relevance of PD-1, PD-L1, and TP63 in patients with diffuse large B-cell lymphoma,Medicine (Baltimore). 2017 Apr; 96(15):e6398.

Xiu, Bing#, Zhang, Wenjun#, Huang, Binbin, Chen, Jingde, Lu, Huina, Fu, Jianfei, Xiong, Hong, Liang, Aibin*, Genetic inhibition of vascular endothelial growth factor receptor-1 significantly inhibits the migration and proliferation of leukemia cells and increases their sensitivity to chemotherapy, Oncology Reports, 2013, 29(5):2030-2038

Yangyang Xu, Zhenchuan Liu, Lixin Lv, Ping Li, Bing Xiu, Wenbin Qian, Aibin Liang，MiRNA-340-5p mediates the functional and infiltrative promotion of tumor-infiltrating CD8+ T lymphocytes in human diffuse large B cell lymphoma. J Exp Clin Cancer Res,2020,39(1):238

Xiu Luo#, Huina Lu#, Bing Xiu, Hao Wu, Bing Li, Ping Li, Yuhua Chen, ili Zhou, Wenjun Zhang, Yan Dong, Aibin Liang, Yi Ding*. The efficacy and safety of combined immunosuppressive therapy plus umbilical cord blood infusion in severe aplastic anemia patients: a cohort study. Experimental and Therapeutic Medicine，2018,15(2):1966-1974

Yang ZZ, Grote DM, Xiu B, Ziesmer SC, Price-Troska TL, Hodge LS, Yates DM, Novak AJ, Ansell SM*,TGF-beta upregulates CD70 expression and induces exhaustion of effector memory T cells in B-cell non-Hodgkin's lymphoma, Leukemia, 2014, 28(9): 1872-1884

会议论文（Conference papers ）：

 Xinyu Zhu, M.D., Bing Xiu, M.D. , Jingjing Zhu , Zhi-Zhang Yang, MD and Aibin Liang, MD.“Paired Circulating Tumor DNA in Cerebrospinal Fluid and Peripheral Blood: Reliable Technology for Diagnosing and Monitoring Primary and Secondary Central Nervous Lymphoma”，65th ASH meeting，2023.12.9-12.12，poster，best of posters.

Xiu Bing, Li Bing , Zhu Xinyu, Xiao Gangfeng , Luo Xiu , Fu Jianfei, Zhi-zhang Yang, Liang Aibin *. Complete remissions to PD-1 blockade in combination with reduced dose ICE chemotherapy in two cases of relapsed or refractory classical Hodgkin lymphoma with bulky lung involvement after failed PD-1 blockade. ASH meeting abstract. 2021.12.

Bing Xiu, Yi Lin, Deanna M. Grote, Steven C. Ziesmer, Zhizhang Yang, Michael P. Gustafson🤽🏽‍♂️，Mary L. Maas, Zhe (Jenny) Zhang, Allan B. Dietz☦️，Ai-bin Liang🏄🏼，Luis F. Porrata, Anne J. Novak◻️，Stephen M. Ansell*, CD14+CD16-HLADRlow monocytes are increased in the peripheral blood of patients with B-cell non-Hodgkin lymphoma (NHL) and have an immature suppressive phenotype, ASCO Meeting, 2014.5.30-2014.6.3

Bing Xiu, Yi Lin, Deanna M. Grote, Steven C. Ziesmer, Michael P. Gustafson, Mary L. Maas, Zhe (Jenny) Zhang, Allan B. Dietz, Ai-Bin Liang, Luis F. Porrata, Anne J. Novak, Zhi-Zhang Yang, Stephen M. Ansell*, IL-10 Contributes to the Development of Immunosuppressive CD14+HLA-DRlow/- monocytes in B-Cell Non-Hodgkin’s Lymphoma, ASH Annual Meeting, 2014.12.6-2014.12.9